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these patients and the impact of the 
pandemic on their lives. The theme of 
this year’s World Encephalitis Day is 
“Lights, Camera, Action”, with land-
marks around the world, including 
Niagara Falls (Ontario, Canada) and 
the Danube bridges in Vienna (Austria), 
being lit red to raise awareness. Having 
reached more than 186 million people 
around the world in previous years, now 
in 2021, World Encephalitis Day seems 
more relevant than ever before.
Although the neuroscience com mun-
ity struggled to disentangle poten tial 
associations between the influenza 
pandemic of 1917 and encephalitis, the 
link between brain inflammation and 
SARS-CoV-2 is undoubtable.
Coordinated awareness days such 
as the World Encephalitis Day recog-
nise patients’ experiences, and are 
also a valuable opportunity for the 
neuroscience com munity to reflect 
on our own clinical assumptions and 
whether there might be scope for a 
paradigm nudge, if not yet a full shift.
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An extraordinary World 
Encephalitis Day
The COVID-19 pandemic has led to 
the reconsideration not only of public 
health policies and health care pro-
vision, but also of the received wisdom 
on viral effects on the CNS.
At the start of the pandemic, 
no-one anticipated the large number of 
patients who would have neuroinflam -
matory complica tions as a result of 
severe acute respiratory syn drome 
coronavirus 2 (SARS-CoV-2).1 It is now 
clear that non-vascular CNS disorders 
are common neurological complica-
tions of SARS-CoV-2 infection, and that 
patients with these complications often 
require admission to intensive care and 
invasive ventilation.2,3 In particular, 
encephalitis accounts for 5·6–13% of 
neurological manifesta tions,2,4 ranging 
from acute dissemin ated enceph-
alomyelitis to limbic encephalitis.
Neuroimaging studies have shown 
that nearly half of patients with clinical 
evi dence of enceph alitis have MRI 
evidence of CNS inflammation.5 For 
some patients with SARS-CoV-2 infec-
tion, there are clear risk factors—eg, 
the RANBP2 muta tion, which is associ-
ated with acute necrotising enceph-
alopathy. Whereas, for the majority of 
patients, it is unpredictable who will 
have CNS inflam matory responses, and 
it is plausible that there is nothing par-
ticularly unique about SARS-CoV-2, but 
rather that, owing to the large number 
of infected people, rare complications 
are worryingly frequent.1
It is increasingly recognised that 
CNS inflammatory responses to SARS-
CoV-2 range from typical encephalitis, 
with obvious evidence of inflammation 
on routine neuro imaging or CSF 
parameters, to severe encephalopathy, 
which has an as yet poorly under-
stood inflam matory pathophys iol ogy 
representing a spectrum of encephalitis.3
World Encephalitis Day, on 
Feb 22, 2021, will remind us of 
